logo-loader

Cellmid's CEO Maria Halasz leads way with on-market purchase

Published: 05:30 22 Sep 2014 EDT

cellmid_maria_halasz_newer_358_541faca1cfbc8

Cellmid's (ASX:CDY) chief executive officer Maria Halasz has increased her stake in the company through an on-market purchase of shares.

Halasz purchased 370,000 for a consideration of $9,990, or around $0.027 a share. The stock closed at $0.028 on Friday.

Halasz now holds a direct stake of over 1.55 million shares and 12 million (loan) shares, and an indirect stake of:

- (Direct Capital Pty Ltd) of 5.8 million shares and 7 million unlisted options (20 Nov 2014 $0.056), 1.5 million listed options (23 Oct 2016 $0.034); and

- (Direct Capital Group Pty Ltd) 3,515,625 shares and 5 million unlisted options (15 June 2017 $0.032).

Earlier in the month Cellmid reported a 267% increase in total revenue to $2.8 million for the financial year ended 30 June 2014 with revenue from product sales rising more than 112% to $1.15 million.

This follows the first full year of operations for its Consumer Health Business following the acquisition of Advangen Inc and subsequent growth in distribution of its FGF5 inhibitor hair growth products.

The company’s Midkine Business has achieved development milestones with the completion of humanisation and lead antibody (CAB102) selection and the commencement manufacturing for clinical trials. 

It has commenced preparations for its ‘first in men’ clinical studies with reviewing clinical sites and negotiating with principal investigators.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

54 minutes ago